跳至主要内容
临床试验/NCT00949754
NCT00949754已完成2 期

A Multi-Center, Randomized, Double Blind, Active-Controlled, Parallel Group Clinical Study to Evaluate the Dose Effect of Intradermal Injections of Apitox vs. Histamine in Subjects With Osteoarthritis Symptoms of the Knee

Apimeds, Inc.4 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Apimeds, Inc.
入组人数
40
试验地点
4
主要终点
WOMAC

研究概览

简要总结

The study will evaluate Apitox, pure honeybee venom as a treatment for pain and inflammation of osteoarthritis of the knee.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • osteoarthritis of one or both knees
  • on stable NSAID or none due to intolerance
  • women either post menopausal or on stable birth control
  • no clinically significant disease or or abnormal laboratory values
  • signed informed consent, communicate effectively, understand and comply with all study requirements

排除标准

  • serious or unstable medical or psychological condition
  • known sensitivity to honeybee venom, histamine or lidocaine
  • history of asthma
  • any clinically significant ECG abnormalities
  • any clinically significant laboratory values OOR
  • history of drug or alcohol abuse
  • history of joint injury and forms of inflammatory arthritis

研究组 & 干预措施

histamine

Active Comparator

histamine in saline administered ID as active control for Apitox

干预措施: honeybee venom (Apitoxin (Korea) Apitox (USA)) (Drug)

Apitox pure honeybee venom

Experimental

ID study drug

干预措施: honeybee venom (Apitoxin (Korea) Apitox (USA)) (Drug)

结局指标

主要结局

WOMAC

时间窗: 14 days

次要结局

未报告次要终点

研究者

发起方
Apimeds, Inc.
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验